August 28, 2023 7:51am

Playing share pricing in the final week of August

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

Pre-Open Indications: 1 Positive and 5 Negative Indications

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Never leave an investor uninformed! 

Never leave an investor uninformed!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday


Dow futures are UP +0.24% or (+83 points), S&P futures are UP +0.18% or (+7 points) and NASDAQ futures are UP +0.29% or (+42 points) early in the pre-open – so far

Stock futures rose slightly,

European markets were higher,

Asia-Pacific markets were higher.



We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday, indexes rallied as the Dow closed UP +247.48 or +0.73%, the S&P closed UP +29.40 or +0.67% while the Nasdaq closed UP +126.67 points (+0.94%).

For month, the Dow has dropped -3.4% and S&P -4%, while the Nasdaq lost about -5.3%.

Economic Data Docket: this week - August’s Dallas Fed index — ahead of Friday’s monthly jobs report.


Friday’s (8/25) RegMed Investors’ (RMi) closing bell: “sector takes the line of least expectation as sector turns positive. The cell and gene therapy sector has been lost in the mist of uncertainty” …


Ebb and flow:

Q3: August – 7 positive and 12 negative closes

·         July - 1 holiday, 12 positive and 8 negative close

Q2/23 -

·         June -1 Holiday, 8 negative and 11 positive closes

·         May – 10 negative and 12 positive closes

·         April ended - 1 holiday, 8 positive close and 11 negative closes

Q1/23 –-

·         March – ended with 10 positive and 13 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes


Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Negative Indications

Friday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Agenus (AGEN) closed down -$0.02 with a negative -$0.07 or -5.34% pre-open indication

Blueprint Medicine (BPMC) closed up +$0.92 with a negative -$0.99 or -1.96% pre-open indication

Intellia therapeutics (NTLA) closed up +$0.73 with a negative -$0.03 or -0.08% pre-open indication.

Ionis Pharmaceuticals (IONS) closed up +$0.51 with a negative -$0.77 or -1.91% aftermarket (Friday) indication.

Ultragenyx Pharmaceuticals (RARE) closed up +$0.94 with a negative -$1.01 or -2.66% aftermarket (Friday) indication


Positive Indication:

Beam Therapeutics (BEAM) closed up +$0.15 with a positive +$0.29 or +1.25% pre-open indication



I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all, as I try to keep it simple and short!

The stock market was mixed last week; the Nasdaq and S&P advanced, snapping three-week losing streaks.

Stocks started the week on a positive note, tracking Friday’s gains on Wall Street following cautious comments from central bankers at Jackson Hole. China’s support measures for its equities market helped lift sentiment. <Bloomberg>

Let’s get to the point, few adverbs and even fewer adjectives, no vacillating; I get right to the point, telling investors what has meaning and why news or indications matter.

My “posts” are conveyed with a simplicity of language to highlight what is informative. I am mostly an optimist, yet I also believe that patterns exist.

It “ain’t” been a good August for the cell and gene therapy sector as it suffers 6 positive and 11 negative closes so far… which could also be a set-up for profit reaping in view of economic and inflation “readings”

I am NOT confident that some cell and gene therapy sector equities can continue ascending to the upside; unfortunately, it is a “musical chairs” game!

Risk is riskier …

There's ALSO nothing wrong with standing pat in the short run, holding on to sizable existing exposure.

I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.